Published in Cancer Res on August 15, 2005
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat (2007) 3.78
Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A (2008) 2.04
Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res (2010) 1.97
Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer (2010) 1.87
Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer (2010) 1.80
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res (2009) 1.70
Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol (2009) 1.66
Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology (2008) 1.44
Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol (2012) 1.33
The perivascular niche microenvironment in brain tumor progression. Cell Cycle (2010) 1.30
Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28
Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin Cancer Res (2008) 1.21
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther (2009) 1.18
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One (2011) 1.12
Genetics of glioblastoma: a window into its imaging and histopathologic variability. Radiographics (2011) 1.06
The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. Radiat Oncol (2010) 1.04
Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells. BMC Complement Altern Med (2006) 1.04
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget (2016) 1.02
AKT kinase pathway: a leading target in cancer research. ScientificWorldJournal (2013) 1.01
The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia (2015) 0.96
Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3β/β-catenin signaling pathway. PLoS One (2011) 0.96
Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother (2009) 0.95
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol (2011) 0.92
The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther (2011) 0.89
Pediatric low-grade gliomas and the need for new options for therapy: Why and how? Cancer Biol Ther (2009) 0.88
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase. PLoS One (2014) 0.86
H-Ras increases urokinase expression and cell invasion in genetically modified human astrocytes through Ras/Raf/MEK signaling pathway. Glia (2008) 0.85
The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol (2011) 0.83
Current available therapies and future directions in the treatment of malignant gliomas. Biologics (2009) 0.83
c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. Mol Cancer (2010) 0.82
Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane. Br J Pharmacol (2010) 0.81
Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model. Neoplasia (2012) 0.81
Molecular therapies for malignant glioma. Wien Med Wochenschr (2006) 0.81
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism. Mol Cancer Ther (2009) 0.80
Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. Onco Targets Ther (2012) 0.80
Ghrelin reduces liver impairment in a model of concanavalin A-induced acute hepatitis in mice. Drug Des Devel Ther (2015) 0.79
Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness. Cancer Biol Ther (2014) 0.78
Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells. Transl Oncol (2017) 0.77
NETRIN-4 protects glioblastoma cells FROM temozolomide induced senescence. PLoS One (2013) 0.77
In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. Cell Mol Life Sci (2014) 0.76
Review of low-grade gliomas in children--evolving molecular era and therapeutic insights. Childs Nerv Syst (2015) 0.76
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro Oncol (2015) 0.75
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell (2009) 4.94
A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med (2012) 4.64
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev (2009) 4.15
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer (2010) 4.10
Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell (2003) 3.68
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev (2008) 3.50
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell (2010) 3.34
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res (2006) 2.68
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell (2012) 2.50
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res (2002) 2.45
Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res (2004) 2.36
The brain tumor microenvironment. Glia (2011) 2.13
Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem (2004) 2.07
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia (2005) 2.04
Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res (2006) 2.01
Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res (2010) 1.97
Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene (2004) 1.96
Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol (2009) 1.89
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev (2010) 1.82
Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res (2002) 1.82
Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med (2004) 1.76
Notch signaling enhances nestin expression in gliomas. Neoplasia (2006) 1.73
Radiation resistance and stem-like cells in brain tumors. Cancer Cell (2006) 1.70
Molecular imaging of Akt kinase activity. Nat Med (2007) 1.68
Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell (2010) 1.68
The role of radiotherapy following gross-total resection of atypical meningiomas. J Neurosurg (2012) 1.67
The brain tumor microenvironment. Glia (2012) 1.66
Cancer stem cells and survival pathways. Cell Cycle (2008) 1.66
Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol (2009) 1.66
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res (2005) 1.65
Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A (2007) 1.61
Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res (2008) 1.60
p27 deficiency is associated with migration defects in PDGF-expressing gliomas in vivo. Cell Cycle (2010) 1.59
Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene (2004) 1.58
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 1.53
Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett (2005) 1.53
Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO J (2011) 1.49
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48
Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Cancer Res (2005) 1.47
Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop. J Neurosurg Spine (2010) 1.45
miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS One (2012) 1.44
c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia (2003) 1.40
Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation. J Neurosci (2009) 1.38
Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. PLoS One (2011) 1.37
Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia (2008) 1.36
Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma. Mol Syst Biol (2012) 1.36
DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res (2011) 1.33
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
The perivascular niche microenvironment in brain tumor progression. Cell Cycle (2010) 1.30
Glioma formation, cancer stem cells, and akt signaling. Stem Cell Rev (2008) 1.30
Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28
Dissection of the c-Kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer. Proc Natl Acad Sci U S A (2002) 1.26
An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest (2011) 1.25
The ABCG2 resistance network of glioblastoma. Cell Cycle (2009) 1.24
Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol (2008) 1.18
p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Genes Dev (2003) 1.16
Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma. Cancer Res (2012) 1.15
Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. Neurosurg Clin N Am (2007) 1.15
The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Neoplasia (2005) 1.12
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One (2011) 1.12
Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. J Neurooncol (2009) 1.11
Incorporating molecular tools into clinical trials and treatment for gliomas? Curr Opin Neurol (2007) 1.11
Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol (2004) 1.09
MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. Neoplasia (2002) 1.08
A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol (2012) 1.07
MYC expression promotes the proliferation of neural progenitor cells in culture and in vivo. Neoplasia (2002) 1.06
Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. PLoS One (2012) 1.03
Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Res (2007) 1.02
Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization. Cancer Res (2009) 1.01
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol (2011) 1.00
The therapeutic implications of plasticity of the cancer stem cell phenotype. PLoS One (2010) 0.99
Using mice to decipher the molecular genetics of brain tumors. Neurosurgery (2003) 0.99
MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J (2011) 0.98
Stem cells and brain cancer. Exp Cell Res (2005) 0.98
Astrocyte differentiation states and glioma formation. Cancer J (2003) 0.96
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma. PLoS One (2012) 0.96
New strategy for the analysis of phenotypic marker antigens in brain tumor-derived neurospheres in mice and humans. Neurosurg Focus (2008) 0.95
Origins of brain tumors--a disease of stem cells? Nat Clin Pract Neurol (2006) 0.95
Validation of a high-content screening assay using whole-well imaging of transformed phenotypes. Assay Drug Dev Technol (2010) 0.94
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. Ann Neurol (2011) 0.94
Overexpression of c-MYC promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice. Neuron Glia Biol (2004) 0.94
In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. Proc Natl Acad Sci U S A (2014) 0.93
Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner. ACS Nano (2014) 0.93
Yin and yang: cancer-implicated miRNAs that have it both ways. Cell Cycle (2009) 0.92
Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas. J Nucl Med (2008) 0.92
MEF promotes stemness in the pathogenesis of gliomas. Cell Stem Cell (2012) 0.92
Cooperative translational control of gene expression by Ras and Akt in cancer. Trends Mol Med (2004) 0.91
Developmental neurobiology and the origin of brain tumors. J Neurooncol (2004) 0.91
Applications of mouse glioma models in preclinical trials. Mutat Res (2005) 0.91
Identification of global alteration of translational regulation in glioma in vivo. PLoS One (2012) 0.91
PDGF in gliomas: more than just a growth factor? Ups J Med Sci (2012) 0.88
Organ donors with malignant gliomas: an update. Am J Transplant (2004) 0.87
Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma. Cancer Res (2011) 0.86